QA-68

®

MedChemExpress

Cat. No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-150797 C ₆₁ H ₇₂ N ₁₀ O ₁₀ S ₂ 1169.42 Epigenetic Reader Domain Epigenetics Please store the product under the recommended conditions in the Certificate of	CH-OKONCON
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

	ту	
BIOLOGICAL ACTIVI		
Description	QA-68 (QA-68-ZU81) is a pote and cell colony formation. Q click chemistry reagent, it co with molecules containing A	ent bromodomain-containing protein 9 (BRD9) degrader. QA-68 can inhibit cell cycle progression A-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines ^[1] . QA-68 is a ontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) zide groups.
IC ₅₀ & Target	BRD9	
In Vitro	QA-68 (0-1000 nM; 24 h) exhibits antiproliferative activity against MV4-11, SKM-1 and Kasumi-1-luc+ cells, and inhibits BRD9 protein expression in MV4-11, SKM-1, SEM, NALM6, RS4;11 ^[1] . QA-68 (0.1-1000 nM; 4 days) effectively inhibits SKM-1 cell cycle progression ^[1] . QA-68 (1000 nM; 12 days) inhibits colony formation of additional primary AML bone marrow and PBMC cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]	
	Cell Line:	MV4-11, SKM-1 and Kasumi-1-luc+ cells
	Concentration:	0-1000 nM
	Incubation Time:	24 h
	Result:	Exhibited concentration-dependent inhibition of proliferation of MV4-11, SKM-1 and Kasumi-1-luc+ cells with IC ₅₀ of 1-10 nM in MV4;11 and SKM-1, and IC ₅₀ of 10-100 nM in Kasumi-1-luc +, respectively.
	Cell Cycle Analysis ^[1]	
	Cell Line:	SKM-1cells
	Concentration:	0.1, 1, 10, 100 and 1000 nM
	Incubation Time:	6 days
	Result:	Effectively inhibited SKM-1 cell cycle progression.
	(-)	

Western Blot Analysis^[1]

Cell Line:	MV4-11, SKM-1, SEM, NALM6, RS4;11
Concentration:	0, 1, 10, 100 and 1000 nM
Incubation Time:	24 h
Result:	Inhibited BRD9 protein in all tested cell lines.

REFERENCES

[1]. Weisberg E, et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 Jul 19;12(7):110.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA